Pfizer is jointly marketing the drug Eliquis.
2 reports, 2 independent
Updated Sep 10
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Pfizer is jointly marketing the drug Eliquis.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Pricing reversals pose a key risk to Eliquis's market share.1 source
Pfizer is jointly marketing the drug Eliquis.1 source
Keep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Bristol-Myers Squibb
American pharmaceutical company
Related events
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.
- Roivant Sciences licensed a drug from Pfizer for regulatory approval.
- FDA and Pfizer are seeking regulatory approval for their products.
- MarketBeat is providing analyst ratings and tracking the competitive landscape between healthcare companies Pfizer and Lyra Therapeutics.
- Collaboration revenue realization from Pfizer and GSK backing royalty financing for Spero Therapeutics.